semaj83/ctmatch_classification huggingface dataset:
Patient description: Fernandez is a 41 year man who is a professional soccer player. He came to the clinic with itchy foot. Physical exam revealed localized scaling and maceration between the third and fourth of his right toe. It became inflamed and sore, with mild fissuring. The dorsum and sole of the foot was unaffected. There is no pus or tearing in the affected area. He didn't use ant topical ointment on the lesion and has no positive history for any underlying disease such as DM. He smokes 15 cigarettes per day and drinks a beer per day. His family history is positive for hyperlipidemia in her mother and MI in her father. He is in relation with several partners and use condom during the intercourse. His physical exam and lab studies were normal otherwise. Tinea pedis infection confirmed as his diagnosis by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination.

Clinical trial eligibility criteria: eligible ages (years): 10.0-999.0,  Tinea Pedis Male or female at least 10 years of age, and otherwise healthy Clinically and mycologically confirmed diagnosis of symptomatic tinea pedis In good health with no clinically significant disease that might have interfered with study evaluations Study participant or legal guardian was willing and able to read and sign an IRB approved ICF, which included agreement to comply with all study requirements as indicated in the protocol. For subjects 10 to 17 years of age, an assent form for minors was completed  History of hypersensitivity or allergy to ciclopirox Had any skin condition that would interfere with the diagnosis or assessment of tinea pedis Had a history of dermatophyte infecton unresponsive to antifungal treatment Had a history of alcoholism, drug abuse, or problems that would likely have made the subject unreliable for the study Had any condition or used any medication that, in the opinion of the Investigator, might have interfered with the conduct or results of the study or placed the prospective subject at increased risk Was unwilling to sign the informed consent Female who was pregnant or lactating
Patient description: Fernandez is a 41 year man who is a professional soccer player. He came to the clinic with itchy foot. Physical exam revealed localized scaling and maceration between the third and fourth of his right toe. It became inflamed and sore, with mild fissuring. The dorsum and sole of the foot was unaffected. There is no pus or tearing in the affected area. He didn't use ant topical ointment on the lesion and has no positive history for any underlying disease such as DM. He smokes 15 cigarettes per day and drinks a beer per day. His family history is positive for hyperlipidemia in her mother and MI in her father. He is in relation with several partners and use condom during the intercourse. His physical exam and lab studies were normal otherwise. Tinea pedis infection confirmed as his diagnosis by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination.

Clinical trial eligibility criteria: eligible ages (years): 10.0-999.0,  Tinea Pedis Male or female at least 10 years of age, and otherwise healthy Clinically and mycologically confirmed diagnosis of symptomatic tinea pedis In good health with no clinically significant disease that might have interfered with study evaluations Study participant or legal guardian was willing and able to read and sign an IRB approved ICF, which included agreement to comply with all study requirements as indicated in the protocol. For subjects 10 to 17 years of age, an assent form for minors was completed  History of hypersensitivity or allergy to ciclopirox Had any skin condition that would interfere with the diagnosis or assessment of tinea pedis Had a history of dermatophyte infection unresponsive to antifungal treatment Had a history of alcoholism, drug abuse, or problems that would likely have made the subject unreliable for the study Had any condition or used any medication that, in the opinion of the Investigator, might have interfered with the conduct or results of the study or placed the prospective subject at increased risk Was unwilling to sign the informed consent Female who was pregnant or lactating
Patient description: Fernandez is a 41 year man who is a professional soccer player. He came to the clinic with itchy foot. Physical exam revealed localized scaling and maceration between the third and fourth of his right toe. It became inflamed and sore, with mild fissuring. The dorsum and sole of the foot was unaffected. There is no pus or tearing in the affected area. He didn't use ant topical ointment on the lesion and has no positive history for any underlying disease such as DM. He smokes 15 cigarettes per day and drinks a beer per day. His family history is positive for hyperlipidemia in her mother and MI in her father. He is in relation with several partners and use condom during the intercourse. His physical exam and lab studies were normal otherwise. Tinea pedis infection confirmed as his diagnosis by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Peyronie's Disease Subjects with stable Peyronie's plaques Males at least 18 years of age Must give informed consent  Subjects in the active phase of Peyronie's disease Subjects with less than 1 year history of Peyronie's disease Subjects taking oral medications for Peyronie's disease which Trental, Viagra, vitamin E, colchicines, L-arginine, and tamoxifen. There will be a 2 week wash-out period if patients are on these medications Subjects with more than 1 penile plaque will be excluded from the study Subjects with calcified plaques demonstrated by ultrasound will be excluded from the study Known allergy or sensitivity to any components of the study medication (botulinum toxin A), anesthetics, or any other product associated with the treatment and general study procedures Any medical condition or neuromuscular disorder that may put the patient at increased risk with exposure to botulinum toxin A (BTX-A), including myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis Patient taking aminoglycosides or any drug known to interfere with neuromuscular transmission Patient has hemophilia or other clotting factor deficiencies or disorders that cause bleeding diathesis Patient must not be taking aspirin, non-steroidal anti-inflammatory drugs, or Coumadin for 7 or more days prior to Botox injection
Patient description: Fernandez is a 41 year man who is a professional soccer player. He came to the clinic with itchy foot. Physical exam revealed localized scaling and maceration between the third and fourth of his right toe. It became inflamed and sore, with mild fissuring. The dorsum and sole of the foot was unaffected. There is no pus or tearing in the affected area. He didn't use ant topical ointment on the lesion and has no positive history for any underlying disease such as DM. He smokes 15 cigarettes per day and drinks a beer per day. His family history is positive for hyperlipidemia in her mother and MI in her father. He is in relation with several partners and use condom during the intercourse. His physical exam and lab studies were normal otherwise. Tinea pedis infection confirmed as his diagnosis by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination.

Clinical trial eligibility criteria: eligible ages (years): 15.0-70.0,  Asthma Patient is male or female, at least 15 years of age and no more than 70 years Patient has mild persistent asthma (step 2) of the Guidelines for the Diagnosis and Management of Asthma issued by the National Heart, Lung, and Blood Institute of the National Institutes of Health as defined by a history of symptoms at least once a week but less than daily (step 2) (5) Current asthma treatment includes short-acting inhaled β-agonist alone as needed Patient fulfils all the following signs and symptoms of asthma History of symptoms including, but not limited to dyspnea, wheezing, chest tightness, cough, or sputum production for at least 12 months A forced expiratory volume in one second (FEV1) of at least 80% of the predicted value (pre-bronchodilator) while withholding β-agonist for at least six hours Patient has a diagnosis of asthma as defined by 1) an increase in FEV1 or PEF of ≥12% (absolute value), 20 to 30 minutes after inhaled β-agonist administration, OR 2) a positive methacholine PC20 (provocative concentration causing a 20% fall in FEV1) of 8 mg/ml or lower which was performed within the previous 12 months, OR 3) a fall in FEV1 of at least 15% after an exercise challenge which was performed within the previous 12 months. β-agonist reversibility and the methacholine and exercise challenge tests may be satisfied within the previous 12 months if there is adequate source documentation Patients demonstrate symptoms requiring β-agonist use on ≥2 and ≤6 days of the week for the previous two weeks Patient is able to chew a tablet Patient is judged to be in good, stable physical and mental health (except for his/her asthma) based on the medical history, physical examination, and routine laboratory data, and appears able to successfully complete this trial  none
Patient description: Fernandez is a 41 year man who is a professional soccer player. He came to the clinic with itchy foot. Physical exam revealed localized scaling and maceration between the third and fourth of his right toe. It became inflamed and sore, with mild fissuring. The dorsum and sole of the foot was unaffected. There is no pus or tearing in the affected area. He didn't use ant topical ointment on the lesion and has no positive history for any underlying disease such as DM. He smokes 15 cigarettes per day and drinks a beer per day. His family history is positive for hyperlipidemia in her mother and MI in her father. He is in relation with several partners and use condom during the intercourse. His physical exam and lab studies were normal otherwise. Tinea pedis infection confirmed as his diagnosis by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination.

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Tinea Versicolor Male or female patients, aged 19 years and over. 2. Clinical presentation of tinea versicolor. 3. Positive KOH using calcofluor. 4. The ability to provide informed consent (including photography release)  Use of topical antifungal to the affected area in the past 30 days 2. Use of topical steroid to the affected area in the past 14 days 3. If female, positive urine pregnancy test at screening (female patients of childbearing potential must be practicing a reliable method of birth control, not be planning a pregnancy, not be breast-feeding during the study) 4. Patients with a dermatologic condition in the region of the treatment site that in the investigator's opinion may interfere with the study results 5. Current diagnosis of immunocompromising conditions 6. Any medical or psychiatric condition that may interfere with treatment or compliance
Patient description: Fernandez is a 41 year man who is a professional soccer player. He came to the clinic with itchy foot. Physical exam revealed localized scaling and maceration between the third and fourth of his right toe. It became inflamed and sore, with mild fissuring. The dorsum and sole of the foot was unaffected. There is no pus or tearing in the affected area. He didn't use ant topical ointment on the lesion and has no positive history for any underlying disease such as DM. He smokes 15 cigarettes per day and drinks a beer per day. His family history is positive for hyperlipidemia in her mother and MI in her father. He is in relation with several partners and use condom during the intercourse. His physical exam and lab studies were normal otherwise. Tinea pedis infection confirmed as his diagnosis by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Tinea Pedis Microbiologically confirmed clinical diagnosis of interdigital tinea pedis If female and of child bearing potential, prepare to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g., condom, intra-uterine device (IUD), oral, transdermal, injected or implanted hormonal contraceptives) A confirmed clinical diagnosis of interdigital tinea pedis. Lesions are to be predominately interdigital but may extend to other areas of the foot (the non-interdigital lesions must not be hyperkeratotic) The presence of tinea pedis infection, confirmed by the observation of segmented fungal hyphae during a microscopic potassium hydroxide (KOH) wet mount examination (potassium hydroxide mount preparation) Identification of an appropriate dermatophyte by culture sent to the central laboratory. The appropriate dermatophytes are Trichophyton rubrum, Trichophyton mentagrophyte or Epidermophyton floccosum  Use of any of the following within the indicated timeline Oral or injectable steroids Any oral anti-fungals within 4 weeks of the study start Use of topical corticosteroids or any other topical antipruritics on the feet within 72 hours of the study start Any prescription or over-the-counter (OTC) topical antifungals on the feet within two weeks prior to study entry Use of any antihistamines within 72 hours of the study start Any known hypersensitivity to butenafine or other antifungal agents Evidence of any concurrent dermatophytic infection of toe nails (onychomycosis) or other dermatological condition of the foot that may interfere with the Investigator's evaluation of tinea pedis Patients with recurrent tinea pedis (more than 3 infections in the past 12 months) who have been unresponsive to previous antifungal therapy
Patient description: Fernandez is a 41 year man who is a professional soccer player. He came to the clinic with itchy foot. Physical exam revealed localized scaling and maceration between the third and fourth of his right toe. It became inflamed and sore, with mild fissuring. The dorsum and sole of the foot was unaffected. There is no pus or tearing in the affected area. He didn't use ant topical ointment on the lesion and has no positive history for any underlying disease such as DM. He smokes 15 cigarettes per day and drinks a beer per day. His family history is positive for hyperlipidemia in her mother and MI in her father. He is in relation with several partners and use condom during the intercourse. His physical exam and lab studies were normal otherwise. Tinea pedis infection confirmed as his diagnosis by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Tinea Pedis Otherwise healthy patients with laboratory proven tinea pedis  Age lower than 18 and higher than 80
Patient description: Fernandez is a 41 year man who is a professional soccer player. He came to the clinic with itchy foot. Physical exam revealed localized scaling and maceration between the third and fourth of his right toe. It became inflamed and sore, with mild fissuring. The dorsum and sole of the foot was unaffected. There is no pus or tearing in the affected area. He didn't use ant topical ointment on the lesion and has no positive history for any underlying disease such as DM. He smokes 15 cigarettes per day and drinks a beer per day. His family history is positive for hyperlipidemia in her mother and MI in her father. He is in relation with several partners and use condom during the intercourse. His physical exam and lab studies were normal otherwise. Tinea pedis infection confirmed as his diagnosis by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Tinea Pedis Subjects of either gender must be 12 years of age or older. 2. Subjects with a clinical diagnosis of interdigital tinea pedis on one or both feet characterized by clinical evidence of a tinea infection (at least moderate erythema, moderate scaling, and mild pruritus) based on signs and symptoms. 3. Subjects with a mycological diagnosis of interdigital tinea pedis confirmed by the detection of fungal hyphae on a microscopic KOH wet mount 4. Females of child-bearing potential must have a negative urine pregnancy test and must agree to use an effective form of contraception  Subjects with moccasin (dry type) tinea pedis; with concomitant onychomycosis of the fingernails and/or toenails on the evaluated foot, with severe dermatophytoses, a concurrent tinea infection or bacterial skin infection on the evaluated foot; 2. Female subjects who are pregnant and/or nursing or planning a pregnancy during the course of the trial. 3. Subjects who are immunocompromised (due to disease, e.g., HIV or medications 4. Subjects with a history of intolerance or hypersensitivity to imidazole compounds or the inactive components of the cream; 5. Subjects with a life-threatening condition (e.g., autoimmune deficiency syndrome, cancer, unstable angina, or myocardial infarction) within the last 6 months. 6. Subjects using the following medications: 1. topical antifungal agent within 30 days of the baseline visit 2. systemic antifungals within 8 weeks of the baseline visit (8 months for oral terbinafine) 3. topical corticosteroid in treatment area(s) within 30 days of the baseline visit. 4. systemic corticosteroids within 30 days of the baseline visit; 5. any other topical medicated topical treatments to the treatment area(s) within 7 days of baseline visit
Patient description: Fernandez is a 41 year man who is a professional soccer player. He came to the clinic with itchy foot. Physical exam revealed localized scaling and maceration between the third and fourth of his right toe. It became inflamed and sore, with mild fissuring. The dorsum and sole of the foot was unaffected. There is no pus or tearing in the affected area. He didn't use ant topical ointment on the lesion and has no positive history for any underlying disease such as DM. He smokes 15 cigarettes per day and drinks a beer per day. His family history is positive for hyperlipidemia in her mother and MI in her father. He is in relation with several partners and use condom during the intercourse. His physical exam and lab studies were normal otherwise. Tinea pedis infection confirmed as his diagnosis by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination.

Clinical trial eligibility criteria: eligible ages (years): 2.0-90.0,  Hypersensitivity, Immediate Autoinflammatory Syndromes Physical Urticaria Familial Cold Autoinflammatory Syndromes Affected subjects/guardian must: 1. Be at least 2 years of age and no older than 90 years of age. 2. Have a history of a physical urticaria, which has been evaluated by the patient's healthcare practitioner. 3. Provide copies of pertinent medical history and laboratory studies. 4. Have a health care provider outside of NIH. 5. Be willing to give informed consent. 6. Be willing to donate blood for sample storage to be used for future research. Non-affected relatives/guardian must: 1. Be at least 2 years of age and no older than 90 years of age. 2. Have a relative who is enrolled on this protocol and is known to have documented history of a physical urticaria. 3. Not have a history of physical urticaria. 4. Be willing to give informed consent. 5. Be willing to donate blood for sample storage to be used for future research. Normal volunteers must: 1. Be 18-65 years of age. 2. Be non-atopic (not have a history of allergic rhinitis, asthma, atopic dermatitis) per subject s medical history. 3. Have the ability to give informed consent. 4. Be willing to donate blood for sample storage to be used for future research. 5. Not have a history of physical urticaria  The following apply to all subjects: 1. Presence of conditions which, in the judgment of the investigator or the referring physician, may put the subject at undue risk, such as acute infection, severe thrombocytopenia (minimum platelet count of 30,000), or significant cardiovascular disease 2. Any condition that in the view of the principal investigator (PI) would make the subject unsuitable for enrollment in this study 3. History of HIV or other known immunodeficiency 4. History or evidence of chronic Hepatitis B and/or C infection 5. Pregnancy
Patient description: Fernandez is a 41 year man who is a professional soccer player. He came to the clinic with itchy foot. Physical exam revealed localized scaling and maceration between the third and fourth of his right toe. It became inflamed and sore, with mild fissuring. The dorsum and sole of the foot was unaffected. There is no pus or tearing in the affected area. He didn't use ant topical ointment on the lesion and has no positive history for any underlying disease such as DM. He smokes 15 cigarettes per day and drinks a beer per day. His family history is positive for hyperlipidemia in her mother and MI in her father. He is in relation with several partners and use condom during the intercourse. His physical exam and lab studies were normal otherwise. Tinea pedis infection confirmed as his diagnosis by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Stroke Mobility be an inpatient at the Nova Scotia Rehabilitation Centre with a primary diagnosis of stroke within the previous 6 months be competent to provide informed consent have permission of the attending physician to participate require no more than minimal assistance for verbal/non-verbal communication and auditory comprehension as evaluated by a therapist or by chart review of the baseline CIHI evaluation;27 be able to attend during a 20-minute therapy session as evaluated by the occupational or physical therapist use a manual wheelchair for at least 1 hour per day be able to be safely seated in the power wheelchair that we will be using for the study have no significant visual impairment (such that a subject would be unable to see barriers) as evaluated by his/her therapist based on his/her performance during functional tasks Not currently be using a power wheelchair have no physical or mental health condition (as determined by the health-care team) that would make participation dangerous  none